BSE filing, NSE: BALAMINES. Summary written from the filing by ALFA Finder's alert engine.
Balaji Amines Ltd: key numbers
- Share price
- ₹1,854.10
- Market cap
- ₹6,007 Cr
- Revenue (annual)
- ₹1,425 Cr
- Net profit (annual)
- ₹167.2 Cr
- P/E (TTM)
- 29.5×Sector 34.5×
- Promoter holding
- 54.56%+0.00% QoQ
- FII holding
- 3.25%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Balaji Amines Ltd
All →Balaji Amines Board Meeting Date
Balaji Amines scheduled a board meeting on 2 November 2026 for September 2026 quarter and half-year results. Trading window reopens 48 hours after results.
Balaji Amines Other Announcement
The company filed its quarterly shareholding pattern under Regulation 31(1)(b) of the SEBI LODR Regulations for the period ended September 30, 2026.
Balaji Amines Other Announcement
Balaji Amines has filed the Regulation 74(5) certificate for the quarter ended September 30, 2026, as received from its registrar, Venture Capital and Corporate Investments.
Balaji Amines Legal & Regulatory
Balaji Amines Ltd's license (3111001781) was placed on the Denied Entity List by the DGFT due to export obligation violations. The company reports no material financial impact.
Balaji Amines Management Change
Mr. Rajendrakumar Mohanprasad Tapadiya completed his second term as an Independent Director on the board of Balaji Speciality Chemicals Limited, a material subsidiary of Balaji Amines.
Balaji Amines Production Started
Balaji Amines has commenced commercial production at its enhanced Acetonitrile (ACN) plant in Solapur. Total installed capacity reached 1,440 TPM following the successful expansion and modernisation programme.
- Acetonitrile (ACN) production capacity
- 1440.0 TPM
Other other announcement announcements
All →Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.
Shriram Asset Management Company Other Announcement
Shriram AMC filed ICRA's quarterly monitoring agency report on preferential issue proceeds. Utilisation is in line with the offer objects, with no deviation reported.
Jhandewalas Foods Other Announcement
Jhandewalas Foods filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing records holdings by category and contains no transaction or money event.
Avience Biomedicals Other Announcement
Avience Biomedicals confirmed corporate governance compliance is not applicable, as it is SME-listed on NSE Emerge. No quarterly governance report is required for September 2026.